The company said it recorded net sales of $4.663 billion in Q1 2025, up 20.9% on a reported basis, 22.2% on an operational basis and 18.2% on an organic basis versus the prior year period.

1. 01

   The company said it recorded net sales of $4.663 billion in Q1 2025, up 20.9% on a reported basis, 22.2% on an operational basis and 18.2% on an organic basis versus the prior year period.

2. 02

   Boston Scientific reported GAAP net income attributable to its common stockholders of $674 million, or $0.45 per share, for Q1 2025, and adjusted EPS of $0.75. The company said the prior year period had net income of $495 million, or $0.33 per share, and adjusted EPS of $0.56.

3. 03

   The company said Cardiovascular net sales came to $3,085 million in Q1 2025, up 26.2% on a reported basis, and MedSurg net sales came to $1,577 million, up 11.7%.

4. 04

   Boston Scientific said it expects net sales for Q2 2025 to grow about 17.5 to 19.5% on a reported basis, with adjusted EPS of $0.71 to $0.73. It also expects full-year net sales to grow about 15 to 17% on a reported basis, with adjusted EPS of $2.87 to $2.94.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.